In an 83‑year‑old patient with type 2 diabetes, currently taking dapagliflozin 10 mg daily and an estimated glomerular filtration rate of 59 mL/min/1.73 m², what medication adjustments are appropriate?

Continue Dapagliflozin 10 mg Daily Without Dose Adjustment

For this 83-year-old patient with type 2 diabetes and an eGFR of 59 mL/min/1.73 m², continue dapagliflozin 10 mg daily without any dose modification. This eGFR falls within CKD stage G3a, where dapagliflozin maintains both its glucose-lowering efficacy and, more importantly, its cardiovascular and kidney protective benefits 1.

Why No Adjustment Is Needed

The 2022 ADA/KDIGO consensus guidelines explicitly state that dapagliflozin 10 mg daily is the appropriate dose for patients with eGFR ≥45 mL/min/1.73 m² 1. The FDA label confirms this, specifying that no dose adjustment is required for glycemic control when eGFR is ≥45 mL/min/1.73 m² 2. Your patient's eGFR of 59 is well above this threshold.

The critical distinction: While glucose-lowering efficacy diminishes as eGFR declines, the kidney and cardiovascular protective effects of SGLT2 inhibitors are preserved even at lower eGFR levels 1. This is why the medication should be continued—the benefits extend far beyond glycemic control.

What to Monitor

• eGFR monitoring frequency: Check eGFR at least every 3-6 months given the patient's age and CKD stage 3, 4
• Expect an initial eGFR dip: A transient decline of 2-3 mL/min/1.73 m² within the first 1-2 weeks is normal and represents hemodynamic adjustment, not kidney injury 1, 5. This typically reverses by 2-4 weeks post-initiation, but since your patient is already on treatment, this acute phase has passed
• Volume status: Assess for signs of hypovolemia, particularly in this elderly patient 1, 2
• Genital mycotic infections: More common in women but can occur in men; counsel on hygiene measures 1

When Dose Adjustment Would Be Needed

You would only need to reconsider the dose if:

• eGFR drops below 45 mL/min/1.73 m²: At that point, dapagliflozin becomes ineffective for glucose lowering but should still be continued at 10 mg daily for kidney and cardiovascular protection 1, 2
• eGFR drops below 25 mL/min/1.73 m²: Initiation is not recommended below this threshold, but if already on treatment, continue 10 mg daily for kidney and cardiovascular benefits until dialysis 1, 2

Critical Pitfalls to Avoid

Do not discontinue dapagliflozin based solely on declining eGFR. The DAPA-CKD trial demonstrated that dapagliflozin slows long-term eGFR decline by approximately 1 mL/min/1.73 m² per year compared to placebo 5. In patients with type 2 diabetes specifically, the chronic eGFR slope improved by 2.26 mL/min/1.73 m² per year 5. Stopping the medication prematurely removes this protective effect.

Temporary discontinuation considerations: Hold dapagliflozin for at least 3 days before major surgery or procedures with prolonged fasting to reduce ketoacidosis risk 2. Resume when the patient is clinically stable and eating normally.

Additional Considerations for This Elderly Patient

At age 83, this patient falls into the group where absolute cardiovascular and mortality risks are higher, but the relative benefit of dapagliflozin remains consistent across all age groups, including septuagenarians and octogenarians 6. The DAPA-CKD trial showed no heterogeneity of treatment effect based on age, and ageism should not discourage appropriate use 6.

Given the patient's age, be particularly vigilant for:

• Hypoglycemia risk: If on insulin or sulfonylureas, consider dose reductions of these agents rather than adjusting dapagliflozin 1
• Falls risk: Monitor blood pressure for orthostatic changes, though absolute hypotension risk with SGLT2 inhibitors is low 1

Bottom line: No medication adjustment is warranted at this eGFR. Continue dapagliflozin 10 mg daily and monitor kidney function regularly.